Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone–resistant strains

Table 2 Anatomic origin and microbiologic findings of S. maltophilia bacteremia in study participants

Factors	Survivors N = 44	Non-survivors N = 82	p value
Infection source
Pneumonia	12 (27.9)	23 (28.0)	0.987
Catheter-related infection	15 (34.1)	34 (42.0)	0.202
Intra-abdominal infection	16 (36.4)	22 (27.2)	0.285
Soft tissue infection	0 (0.0)	5 (6.2)	0.161
Urinary tract infection	1 (2.3)	0 (0.0)	0.352
Polymicrobial infection	18 (40.9)	36 (43.9)	0.746
Antibiotics susceptibility
Quinolone resistance	5 (11.6)	34 (41.5)	0.001
TMP-SMX resistance	3 (6.8)	12 (14.6)	0.197
Resistant strain^a	17 (38.6)	49 (59.8)	0.024
Treatment
Empirical antibiotic use
Cephalosporins	2 (4.5)	6 (7.4)	0.711
Carbapenems	13 (29.5)	42 (51.9)	0.016
Fluoroquinolones	13 (29.5)	8 (9.8)	0.004
BLBLIs	14 (31.8)	16 (19.5)	0.122
TMP-SMX	0 (0.0)	0 (0.0)	–
Definitive antibiotic use
Carbapenems	2 (4.5)	16 (19.5)	0.022
Fluoroquinolones	21 (47.7)	19 (23.5)	0.005
BLBLIs	3 (6.8)	5 (6.2)	1.000
TMP-SMX	4 (9.1)	27 (33.3)	0.003
Inappropriate antimicrobial therapy^b, yes	14 (31.8)	25 (30.9)	0.912

Note. BLBLIs Beta-lactam/beta-lactamase inhibitors, TMP-SMX Trimethoprim-sulfamethoxazole
The data were expressed as number (%) or median (interquartile range)
^aResistant strain, Quinolone or/and TMP-SMX resistance
^bAppropriate antimicrobial therapy, the administration of at least one agent to which the index SM isolate was susceptible in vitro

ISSN: 1471-2334